Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997972 | 1.00 | IGF1R (0.78) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6093883 | 0.93 | IGF1R (0.67) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6093894 | 0.93 | IGF1R (0.67) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6096307 | 0.91 | IGF1R (0.65) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5074379 | 0.91 | IGF1R (0.70) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6096299 | 0.91 | IGF1R (0.65) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5074383 | 0.91 | IGF1R (0.70) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5523746 | 0.91 | IGF1R (0.67) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6098486 | 0.91 | IGF1R (0.67) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6098474 | 0.90 | IGF1R (0.70) | IGF1RCYP3A4CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381598-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | claimed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | claimed |
| EP-1381598-A1 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-21 | — | — | EP | claimed |
| WO-2002079192-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
| EP-1670416-A4 | METHODS FOR TREATING IGF1R-INHIBITOR INDUCED HYPERGLYCEMIA | BRISTOL MYERS SQUIBB CO (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1758564-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Brystol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1670416-A2 | METHODS FOR TREATING IGF1R-INHIBITOR INDUCED HYPERGLYCEMIA | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| WO-2005094376-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005034868-A2 | METHODS FOR TREATING IGF1R-INHIBITOR INDUCED HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075358-A1 | Methods for treating IGF1R-inhibitor induced hyperglycemia | BRISTOL-MYERS SQUIBB COMANY | 2005-04-07 | — | — | US | disclosed |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-20040106605-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004030627-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040072760-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072760-A1 | Synergistic methods and compositions for treating cancer | IGF1R, MCL1, IGFBP2 | IGF1R 1/4885CYP3A4 4799/4885CYP1A2 4712/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | IGF1R 216/4885CYP3A4 2334/4885CYP1A2 1415/4885 |
| US-20040106605-A1 | Synergistic methods and compositions for treating cancer | EGFR, IGF1R, ERBB3 | IGF1R 2/4885CYP3A4 4824/4885CYP1A2 4711/4885 |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | IGF1R, CHEK2, MCL1 | IGF1R 1/4885CYP3A4 4810/4885CYP1A2 4699/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | IGF1R 302/4885CYP3A4 2522/4885CYP1A2 1634/4885 |
| US-20050075358-A1 | Methods for treating IGF1R-inhibitor induced hyperglycemia | IGF1R, IGFBP1, IRS1 | IGF1R 1/4885CYP3A4 3956/4885CYP1A2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.